6月29日 - ** Regenxbio（RGNX.O）股价上涨5.9%，至11.10美元
** 这家药物研发公司将在其用于治疗糖尿病视网膜病变的实验性一次性基因疗法surabgene lomparvovec的中后期临床试验中完成首例患者给药后，从合作伙伴艾伯维（AbbVie， ABBV.N）处获得1亿美元的里程碑付款
** 这种与糖尿病相关的眼部疾病是劳动年龄成年人视力丧失的主要原因之一
** 该研究预计将在美国招募约135名患者；RGNX表示，主要目标是评估一年后疾病严重程度的改善
** 计划于7月在一次视网膜专家会议上公布其糖尿病视网膜病变和湿性年龄相关性黄斑变性（wet AMD）项目的长期数据
** 计入盘中涨幅后，RGNX今年以来累计下跌22.6%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.